| Code | CSB-RA021334MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LM-101, targeting Signal Regulatory Protein Alpha (SIRPA, also known as CD172a or SHP substrate-1). SIRPA is an inhibitory receptor expressed primarily on myeloid cells, including macrophages, dendritic cells, and neutrophils, where it plays a critical role in regulating innate immune responses. Upon binding to its ligand CD47, SIRPA transmits "don't eat me" signals that prevent phagocytosis of healthy cells. This immune checkpoint mechanism is frequently exploited by cancer cells that overexpress CD47 to evade immune surveillance, making the SIRPA-CD47 axis an important therapeutic target in oncology research. Dysregulation of SIRPA signaling has also been implicated in autoimmune disorders, inflammatory conditions, and hematological malignancies.
LM-101 is a reference antibody used in studies investigating SIRPA function and its role in immune evasion mechanisms. This biosimilar antibody provides researchers with a reliable tool for exploring SIRPA-mediated signaling pathways, evaluating CD47-SIRPA interactions, and investigating potential immunotherapeutic strategies aimed at enhancing macrophage-mediated tumor clearance.
There are currently no reviews for this product.